What is the evidence of EPA-based therapy for CV prevention?
Video navigation menu
- Effect of EPA on atherosclerotic plaques 1:02
- Low dose omega-3 FAs provide no CV benefit 2:15
- An overview of CV outcomes trials with omega-3 FAs 2:55
- How can the different outcomes be explained? 9:28
This lecture by Lale Tokgözoğlu was part of an accredited symposium "Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides" held during the virtual ESC Congress 2021.
Prof. Lale Tokgözoğlu, MD, is Professor of Cardiology at Hacettepe University, Ankara, Turkey.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Amarin.